1301211-78-8

The only target for E1R (inhibition or enhancement of radioligand binding exceeding 20%) is the sigma receptor. 10 μM E1R does not displace the radioligand, but instead increases the specific binding of a non-selective radioligand ([ ³ H]1,3-di(2-tolyl)guanidine) for the sigma receptor by 38% in Jurkat cells.

E1R demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice. Treatment with E1R (0.1-10 mg/kg; administered ip 60 min before the training session) significantly improves cognitive function in a dose-related manner in mice .